Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients
Aim： To investigate the effects of liraglutide, a glucagon-like peptide-1 （GLP-1） receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Methods： A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this m...
Gespeichert in:
| Veröffentlicht in: | Acta pharmacologica Sinica 2015-02, Vol.36 (2), p.200-208 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 208 |
|---|---|
| container_issue | 2 |
| container_start_page | 200 |
| container_title | Acta pharmacologica Sinica |
| container_volume | 36 |
| creator | Feng, Ping Yu, De-min Chen, Li-ming Chang, Bao-cheng Ji, Qiu-di Li, Shu-ying Zhu, Mei Ding, Sheng-hua Zhang, Bao-zhen Wang, Su-li Li, Hong-tao Lin, Jing-na Wang, Mao-jun Guo, Jian-chao Liu, Jie Liu, Zhong-dong Wu, Shen-tao Yang, Ju-hong |
| description | Aim： To investigate the effects of liraglutide, a glucagon-like peptide-1 （GLP-1） receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Methods： A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with Iiraglutide once dally for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 3.1.5 for Windows. Results： Liraglutide treatment caused significant reduction of the mean body weight （from 86.61±14.09 to 79.10±13.55 kg） and waist circumference （from 101.81±13.96 to 94.29±14.17 cm）, resulting in body weight lose of 5%-10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbAlc levels （from 8.66%±2.17% to 6.92%±0.95%） with HbA1c〈7.0% in 35,37% patients, who had a significantly lower baseline level of HbAlc, but higher baseline levels of C peptide and glucagon. Moreover, liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes. Conclusion： Liraglutide significantly reduces body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Patients with apparent visceral obesity, insulin resistance and a long duration of diabetes may have greater body weight loss whereas patients with high insulin-secreting ability, hyperglucagonemia, and short-duration diabetes may obtain better glycemic contrc with liraglutide. |
| doi_str_mv | 10.1038/aps.2014.136 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4326793</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>663907417</cqvip_id><sourcerecordid>1897391479</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-4bb5a38e0e522f05e103e40d841d1adbe034a0b3592fb6b20259460aed7583783</originalsourceid><addsrcrecordid>eNqFkc2P0zAQxSMEYpeFG2dkwYUDKf5OckFCFV9SJS5wtux4kniV2l3b2VX_e1y1VAUhcbLl-fm9mXlV9ZLgFcGsfa93aUUx4SvC5KPqmjRc1A0V_HG5y4bUHLfsqnqW0i3GjDLSPa2uqJCkYx25rvLGRT3OS3YWUAS79JBQngCZYPfoAdw4ZaS9RQ_apYx6F_tlO0AE3wNyHq0n5yEBCvcQL-hgDo95vwNEkXXaQHY92unswOf0vHoy6DnBi9N5U_38_OnH-mu9-f7l2_rjpu4FwbnmxgjNWsAgKB2wgDIvcGxbTizR1gBmXGPDREcHIw3FVHRcYg22ES1rWnZTfTjq7hazBdsX76hntYtuq-NeBe3UnxXvJjWGe8UZlU3HisDbk0AMdwukrLYu9TDP2kNYkiJt15Q18sL-F5WCciFbjgv65i_0NizRl00cKCwYpq0o1Lsj1ceQUoTh3DfB6pC8KsmrQ_KqJF_wV5eznuHfURegPgKplPwI8cL134KvT_5T8ONd-XLWlJJ1uOGkYb8AzPfEtA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1650530285</pqid></control><display><type>article</type><title>Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Feng, Ping ; Yu, De-min ; Chen, Li-ming ; Chang, Bao-cheng ; Ji, Qiu-di ; Li, Shu-ying ; Zhu, Mei ; Ding, Sheng-hua ; Zhang, Bao-zhen ; Wang, Su-li ; Li, Hong-tao ; Lin, Jing-na ; Wang, Mao-jun ; Guo, Jian-chao ; Liu, Jie ; Liu, Zhong-dong ; Wu, Shen-tao ; Yang, Ju-hong</creator><creatorcontrib>Feng, Ping ; Yu, De-min ; Chen, Li-ming ; Chang, Bao-cheng ; Ji, Qiu-di ; Li, Shu-ying ; Zhu, Mei ; Ding, Sheng-hua ; Zhang, Bao-zhen ; Wang, Su-li ; Li, Hong-tao ; Lin, Jing-na ; Wang, Mao-jun ; Guo, Jian-chao ; Liu, Jie ; Liu, Zhong-dong ; Wu, Shen-tao ; Yang, Ju-hong</creatorcontrib><description>Aim： To investigate the effects of liraglutide, a glucagon-like peptide-1 （GLP-1） receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Methods： A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with Iiraglutide once dally for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 3.1.5 for Windows. Results： Liraglutide treatment caused significant reduction of the mean body weight （from 86.61±14.09 to 79.10±13.55 kg） and waist circumference （from 101.81±13.96 to 94.29±14.17 cm）, resulting in body weight lose of 5%-10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbAlc levels （from 8.66%±2.17% to 6.92%±0.95%） with HbA1c〈7.0% in 35,37% patients, who had a significantly lower baseline level of HbAlc, but higher baseline levels of C peptide and glucagon. Moreover, liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes. Conclusion： Liraglutide significantly reduces body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Patients with apparent visceral obesity, insulin resistance and a long duration of diabetes may have greater body weight loss whereas patients with high insulin-secreting ability, hyperglucagonemia, and short-duration diabetes may obtain better glycemic contrc with liraglutide.</description><identifier>ISSN: 1671-4083</identifier><identifier>EISSN: 1745-7254</identifier><identifier>DOI: 10.1038/aps.2014.136</identifier><identifier>PMID: 25619391</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>2型糖尿病 ; Asian Continental Ancestry Group ; Biomedical and Life Sciences ; Biomedicine ; Body Weight - drug effects ; Diabetes Mellitus, Type 2 - physiopathology ; Female ; Glucagon-Like Peptide 1 - analogs & derivatives ; Glucagon-Like Peptide 1 - therapeutic use ; Humans ; Hypoglycemic Agents - therapeutic use ; Immunology ; Internal Medicine ; Liraglutide ; Male ; Medical Microbiology ; Middle Aged ; Original ; original-article ; Overweight - drug therapy ; Pharmacology/Toxicology ; Vaccine ; Waist Circumference - drug effects ; 中国 ; 平均体重 ; 患者 ; 肥胖 ; 胰高血糖素样肽-1 ; 腰围 ; 超重</subject><ispartof>Acta pharmacologica Sinica, 2015-02, Vol.36 (2), p.200-208</ispartof><rights>CPS and SIMM 2015</rights><rights>Copyright Nature Publishing Group Feb 2015</rights><rights>Copyright © 2015 CPS and SIMM 2015 CPS and SIMM</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-4bb5a38e0e522f05e103e40d841d1adbe034a0b3592fb6b20259460aed7583783</citedby><cites>FETCH-LOGICAL-c510t-4bb5a38e0e522f05e103e40d841d1adbe034a0b3592fb6b20259460aed7583783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/95561A/95561A.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326793/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326793/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25619391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feng, Ping</creatorcontrib><creatorcontrib>Yu, De-min</creatorcontrib><creatorcontrib>Chen, Li-ming</creatorcontrib><creatorcontrib>Chang, Bao-cheng</creatorcontrib><creatorcontrib>Ji, Qiu-di</creatorcontrib><creatorcontrib>Li, Shu-ying</creatorcontrib><creatorcontrib>Zhu, Mei</creatorcontrib><creatorcontrib>Ding, Sheng-hua</creatorcontrib><creatorcontrib>Zhang, Bao-zhen</creatorcontrib><creatorcontrib>Wang, Su-li</creatorcontrib><creatorcontrib>Li, Hong-tao</creatorcontrib><creatorcontrib>Lin, Jing-na</creatorcontrib><creatorcontrib>Wang, Mao-jun</creatorcontrib><creatorcontrib>Guo, Jian-chao</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Liu, Zhong-dong</creatorcontrib><creatorcontrib>Wu, Shen-tao</creatorcontrib><creatorcontrib>Yang, Ju-hong</creatorcontrib><title>Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients</title><title>Acta pharmacologica Sinica</title><addtitle>Acta Pharmacol Sin</addtitle><addtitle>Acta Pharmacologica Sinica</addtitle><description>Aim： To investigate the effects of liraglutide, a glucagon-like peptide-1 （GLP-1） receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Methods： A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with Iiraglutide once dally for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 3.1.5 for Windows. Results： Liraglutide treatment caused significant reduction of the mean body weight （from 86.61±14.09 to 79.10±13.55 kg） and waist circumference （from 101.81±13.96 to 94.29±14.17 cm）, resulting in body weight lose of 5%-10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbAlc levels （from 8.66%±2.17% to 6.92%±0.95%） with HbA1c〈7.0% in 35,37% patients, who had a significantly lower baseline level of HbAlc, but higher baseline levels of C peptide and glucagon. Moreover, liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes. Conclusion： Liraglutide significantly reduces body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Patients with apparent visceral obesity, insulin resistance and a long duration of diabetes may have greater body weight loss whereas patients with high insulin-secreting ability, hyperglucagonemia, and short-duration diabetes may obtain better glycemic contrc with liraglutide.</description><subject>2型糖尿病</subject><subject>Asian Continental Ancestry Group</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Body Weight - drug effects</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Female</subject><subject>Glucagon-Like Peptide 1 - analogs & derivatives</subject><subject>Glucagon-Like Peptide 1 - therapeutic use</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Immunology</subject><subject>Internal Medicine</subject><subject>Liraglutide</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Middle Aged</subject><subject>Original</subject><subject>original-article</subject><subject>Overweight - drug therapy</subject><subject>Pharmacology/Toxicology</subject><subject>Vaccine</subject><subject>Waist Circumference - drug effects</subject><subject>中国</subject><subject>平均体重</subject><subject>患者</subject><subject>肥胖</subject><subject>胰高血糖素样肽-1</subject><subject>腰围</subject><subject>超重</subject><issn>1671-4083</issn><issn>1745-7254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkc2P0zAQxSMEYpeFG2dkwYUDKf5OckFCFV9SJS5wtux4kniV2l3b2VX_e1y1VAUhcbLl-fm9mXlV9ZLgFcGsfa93aUUx4SvC5KPqmjRc1A0V_HG5y4bUHLfsqnqW0i3GjDLSPa2uqJCkYx25rvLGRT3OS3YWUAS79JBQngCZYPfoAdw4ZaS9RQ_apYx6F_tlO0AE3wNyHq0n5yEBCvcQL-hgDo95vwNEkXXaQHY92unswOf0vHoy6DnBi9N5U_38_OnH-mu9-f7l2_rjpu4FwbnmxgjNWsAgKB2wgDIvcGxbTizR1gBmXGPDREcHIw3FVHRcYg22ES1rWnZTfTjq7hazBdsX76hntYtuq-NeBe3UnxXvJjWGe8UZlU3HisDbk0AMdwukrLYu9TDP2kNYkiJt15Q18sL-F5WCciFbjgv65i_0NizRl00cKCwYpq0o1Lsj1ceQUoTh3DfB6pC8KsmrQ_KqJF_wV5eznuHfURegPgKplPwI8cL134KvT_5T8ONd-XLWlJJ1uOGkYb8AzPfEtA</recordid><startdate>20150201</startdate><enddate>20150201</enddate><creator>Feng, Ping</creator><creator>Yu, De-min</creator><creator>Chen, Li-ming</creator><creator>Chang, Bao-cheng</creator><creator>Ji, Qiu-di</creator><creator>Li, Shu-ying</creator><creator>Zhu, Mei</creator><creator>Ding, Sheng-hua</creator><creator>Zhang, Bao-zhen</creator><creator>Wang, Su-li</creator><creator>Li, Hong-tao</creator><creator>Lin, Jing-na</creator><creator>Wang, Mao-jun</creator><creator>Guo, Jian-chao</creator><creator>Liu, Jie</creator><creator>Liu, Zhong-dong</creator><creator>Wu, Shen-tao</creator><creator>Yang, Ju-hong</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7TS</scope><scope>5PM</scope></search><sort><creationdate>20150201</creationdate><title>Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients</title><author>Feng, Ping ; Yu, De-min ; Chen, Li-ming ; Chang, Bao-cheng ; Ji, Qiu-di ; Li, Shu-ying ; Zhu, Mei ; Ding, Sheng-hua ; Zhang, Bao-zhen ; Wang, Su-li ; Li, Hong-tao ; Lin, Jing-na ; Wang, Mao-jun ; Guo, Jian-chao ; Liu, Jie ; Liu, Zhong-dong ; Wu, Shen-tao ; Yang, Ju-hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-4bb5a38e0e522f05e103e40d841d1adbe034a0b3592fb6b20259460aed7583783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>2型糖尿病</topic><topic>Asian Continental Ancestry Group</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Body Weight - drug effects</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Female</topic><topic>Glucagon-Like Peptide 1 - analogs & derivatives</topic><topic>Glucagon-Like Peptide 1 - therapeutic use</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Immunology</topic><topic>Internal Medicine</topic><topic>Liraglutide</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Middle Aged</topic><topic>Original</topic><topic>original-article</topic><topic>Overweight - drug therapy</topic><topic>Pharmacology/Toxicology</topic><topic>Vaccine</topic><topic>Waist Circumference - drug effects</topic><topic>中国</topic><topic>平均体重</topic><topic>患者</topic><topic>肥胖</topic><topic>胰高血糖素样肽-1</topic><topic>腰围</topic><topic>超重</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feng, Ping</creatorcontrib><creatorcontrib>Yu, De-min</creatorcontrib><creatorcontrib>Chen, Li-ming</creatorcontrib><creatorcontrib>Chang, Bao-cheng</creatorcontrib><creatorcontrib>Ji, Qiu-di</creatorcontrib><creatorcontrib>Li, Shu-ying</creatorcontrib><creatorcontrib>Zhu, Mei</creatorcontrib><creatorcontrib>Ding, Sheng-hua</creatorcontrib><creatorcontrib>Zhang, Bao-zhen</creatorcontrib><creatorcontrib>Wang, Su-li</creatorcontrib><creatorcontrib>Li, Hong-tao</creatorcontrib><creatorcontrib>Lin, Jing-na</creatorcontrib><creatorcontrib>Wang, Mao-jun</creatorcontrib><creatorcontrib>Guo, Jian-chao</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Liu, Zhong-dong</creatorcontrib><creatorcontrib>Wu, Shen-tao</creatorcontrib><creatorcontrib>Yang, Ju-hong</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Physical Education Index</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Acta pharmacologica Sinica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feng, Ping</au><au>Yu, De-min</au><au>Chen, Li-ming</au><au>Chang, Bao-cheng</au><au>Ji, Qiu-di</au><au>Li, Shu-ying</au><au>Zhu, Mei</au><au>Ding, Sheng-hua</au><au>Zhang, Bao-zhen</au><au>Wang, Su-li</au><au>Li, Hong-tao</au><au>Lin, Jing-na</au><au>Wang, Mao-jun</au><au>Guo, Jian-chao</au><au>Liu, Jie</au><au>Liu, Zhong-dong</au><au>Wu, Shen-tao</au><au>Yang, Ju-hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients</atitle><jtitle>Acta pharmacologica Sinica</jtitle><stitle>Acta Pharmacol Sin</stitle><addtitle>Acta Pharmacologica Sinica</addtitle><date>2015-02-01</date><risdate>2015</risdate><volume>36</volume><issue>2</issue><spage>200</spage><epage>208</epage><pages>200-208</pages><issn>1671-4083</issn><eissn>1745-7254</eissn><abstract>Aim： To investigate the effects of liraglutide, a glucagon-like peptide-1 （GLP-1） receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Methods： A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with Iiraglutide once dally for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 3.1.5 for Windows. Results： Liraglutide treatment caused significant reduction of the mean body weight （from 86.61±14.09 to 79.10±13.55 kg） and waist circumference （from 101.81±13.96 to 94.29±14.17 cm）, resulting in body weight lose of 5%-10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbAlc levels （from 8.66%±2.17% to 6.92%±0.95%） with HbA1c〈7.0% in 35,37% patients, who had a significantly lower baseline level of HbAlc, but higher baseline levels of C peptide and glucagon. Moreover, liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes. Conclusion： Liraglutide significantly reduces body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Patients with apparent visceral obesity, insulin resistance and a long duration of diabetes may have greater body weight loss whereas patients with high insulin-secreting ability, hyperglucagonemia, and short-duration diabetes may obtain better glycemic contrc with liraglutide.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>25619391</pmid><doi>10.1038/aps.2014.136</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1671-4083 |
| ispartof | Acta pharmacologica Sinica, 2015-02, Vol.36 (2), p.200-208 |
| issn | 1671-4083 1745-7254 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4326793 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | 2型糖尿病 Asian Continental Ancestry Group Biomedical and Life Sciences Biomedicine Body Weight - drug effects Diabetes Mellitus, Type 2 - physiopathology Female Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptide 1 - therapeutic use Humans Hypoglycemic Agents - therapeutic use Immunology Internal Medicine Liraglutide Male Medical Microbiology Middle Aged Original original-article Overweight - drug therapy Pharmacology/Toxicology Vaccine Waist Circumference - drug effects 中国 平均体重 患者 肥胖 胰高血糖素样肽-1 腰围 超重 |
| title | Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A26%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liraglutide%20reduces%20the%20body%20weight%20and%20waist%20circumference%20in%20Chinese%20overweight%20and%20obese%20type%202%20diabetic%20patients&rft.jtitle=Acta%20pharmacologica%20Sinica&rft.au=Feng,%20Ping&rft.date=2015-02-01&rft.volume=36&rft.issue=2&rft.spage=200&rft.epage=208&rft.pages=200-208&rft.issn=1671-4083&rft.eissn=1745-7254&rft_id=info:doi/10.1038/aps.2014.136&rft_dat=%3Cproquest_pubme%3E1897391479%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1650530285&rft_id=info:pmid/25619391&rft_cqvip_id=663907417&rfr_iscdi=true |